Doximity acquires Ai Startup Pathway Medical for 63 million US dollars

Doximity on the New York stock exchange for the first public offer on June 24, 2021.

Source: NYSE

Doximity Immerse yourself in artificial intelligence and announces the takeover of Startup Pathway Medical for 63 million US dollars on Thursday.

Pathway has created a AI-driven clinical reference instrument with which doctors can ask questions about guidelines, medication and studies. Pathway's answers are synthesized from medical literature, and Doximity said that the startup based in Montreal has one of the largest structured data records in medicine.

The platform of doximity, which has been referred to for doctors for years, helps the clinicians to stay up to date in medical news, find paperwork, find transfers and to carry out telEAALT appointments with patients. By acquiring paths, Doximity hopes that doctors will also contact the platform to answer their clinical questions.

“We hunted up and low, and I think we found the best company in the room to answer the questions of doctors with AI, and it was not in Silicon Valley,” said Jeff Tangney, co -founder and CEO of doximity, to CNBC in an interview.

The deal ended at the end of July due to a cash view of 26 million US dollars and up to 37 million US dollars in additional equity grants, said Doximity.

According to Tangney, the integration of doximity is in full swing, and companies are testing a combined product with thousands of doctors.

In the meantime, patients regularly turn to AI tools and chatbots to get answers to health-related questions.

While a live stream on Thursday, in which Openai announced his new model GPT-5, CEO Sam Altman said that health questions were one of the largest categories of chatt use, a contribution to X and added that the new model in this area was “much better”.

Doximity already has a free AI product, doximity GPT, with which doctors can generate insurance letters and summarize patient diagrams and reports. Pathway will bring additional “robustness” to the data that Doximity has in the back, said Dr. Amit Phull, Chief Clinical Experience Officer from Doximity.

“What Pathway brings this party or this marriage is that you have a very, very robust back-end data set that connects doses of guidelines for literature to quotes,” Phull told CNBC in an interview.

The Pathway model achieved 96% in the US Medical Licining Examination Benchmark, said Doximity, which doctors have to prove that they can understand and use medical knowledge.

In doximity, which went to the stock exchange in 2021, 10% rose by 10% this year after it rose by 90% in 2024. The company has a market capitalization of around 11 billion US dollars.

The stocks of doximity rose by about 6% on Thursday, after the company had reported results in the first quarter, the estimates exceeded the estimates. Sales rose by 15% to $ 145.9 million compared to the previous year, while analysts expected sales of USD 139.5 million according to LSEG. The result per share of 36 cents exceeded the 30-cent average estimation.